![Placeholder Image Placeholder Image](https://prod1.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe
-
Media ReleaseNovartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
-
Media ReleaseSandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle
-
Media ReleaseSandoz Resolves Generic Drug Antitrust Investigation in the U.S.
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Media ReleaseNovartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
-
Media ReleaseAveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
-
Media ReleaseNovartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
-
Media ReleaseNovartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19
-
Media ReleaseNovartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützen
Pagination
- ‹ Previous page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- …
- 16
- › Next page